Do Activated Retinal Microglia Mediate Neurotoxicity In Background Diabetic Retinopathy?
Funder
National Health and Medical Research Council
Funding Amount
$435,589.00
Summary
Diabetic retinopathy, a frequent complication of Type 1 and Type 2 diabetes, is the commonest cause of blindness in working age individuals. Prior to the growth of blindness-causing new vessels in the eye we now know that there is a gradual loss of neurons in the retina. This project will investigate whether the resident immune cells in the retina, which are normally neuroprotective, become neurotoxic during episodes of systemic inflammation (e.g. bacterial or viral infections).
The goal of this research is to improve outcomes for people at risk of becoming blind or visually impaired. The focus is on those who require a corneal transplant, or who suffer from inflammatory eye disease or painful disease of the ocular surface, on neonates with retinopathy of prematurity, or those with the eye disease, keratoconus. We will investigate new treatment options for eye diseases and will examine the evidence for the success of surgical and other therapeutic interventions.
Functional Analysis Of Recently Identified Novel Glaucoma Genes.
Funder
National Health and Medical Research Council
Funding Amount
$519,918.00
Summary
Glaucoma is the commonest cause of irreversible blindness in the world. Recently, through genetic studies in cohorts of blinding glaucoma cases from Australia, our group has found that variants in two genes increase the risk of blinding glaucoma. This project will investigate how these genes contribute to pathological changes in the optic nerve and retina, at the back of the eye, that lead to glaucoma. This knowledge will be useful for developing new strategies to treat glaucoma.
Nanoparticle-based Anti-VEGF Treatment For Ocular Neovascularization
Funder
National Health and Medical Research Council
Funding Amount
$576,921.00
Summary
Diseases like AMD and DR are the leading cause for substantial and irreversible vision loss as a direct effect of pathologic ocular neovascularization and have a significant economic impact on individuals, families, health systems and countries. Nowadays, the treatment requires frequent intravitreal injections of anti-VEGF antibody with all the risks of an invasive intraocular procedure. Nanotechonoly-based drug delivery system will provide a less invasive treatment for this kind of disease.
A System For Measurement Of Vision-specific Quality Of Life Using Item Banking And Computer Adaptive Testing (ViSBank)
Funder
National Health and Medical Research Council
Funding Amount
$831,155.00
Summary
When evaluating medical treatments, it is important to consider all effects from the patient’s perspective; their quality of life. This project utilises new technology to develop an adaptable, computerised, internet-based system to measure the effects of eye diseases and their treatments on patients’ quality of life. This system will provide for more accurate, precise and efficient measurement than existing methods.
Therapeutics For Repair And Regeneration Of The Cornea
Funder
National Health and Medical Research Council
Funding Amount
$166,087.00
Summary
Corneal disease is the commonest cause of irreversible blindness and of the 50 million people world-wide who are bilaterally blind, 10 million are blind from corneal involvement. This proposal will address corneal disease by 1. innovative translational research for corneal repair and regeneration; 2. developing evidence-based management guidelines for corneal disease, and 3. by optimising health service delivery.
Dissecting The Great Ophthalmic Masquerade: The Global Giant Cell Arteritis Genomics Consortium.
Funder
National Health and Medical Research Council
Funding Amount
$583,269.00
Summary
Giant cell arteritis (GCA) is the most common form of vasculitis in people over 50 years of age. If untreated it can cause catastrophic complications including blindness, though this can be prevented if treated early. Although there is clear evidence for a role of genetic factors in GCA, these have been little studied. We have established an Australian-led International consortium, with clinical, basic science and statistical expertise to thoroughly investigate this devastating disease.
The Influence Of Aqueous And Plasma Cytokines In Treatment Outcomes For Diabetic Macular Oedema
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Diabetic macular oedema (DME) is the commonest cause of central visual loss in diabetics and has been linked to increased levels of vascular endothelial growth factor (VEGF) in the eye. DME is treated with anti-VEGF injections, but these need to be repeated, with some patients failing to respond. We plan to see if levels of VEGF and other inflammatory markers will predict treatment response, so those unlikely to respond can be spared futile treatment and receive alternative treatment earlier.